Nexvet Biopharma plc Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nexvet Biopharma (NVET) IPO Opens Down 9%
February 5, 2015 11:06 AM ESTToday's IPO for Nexvet Biopharma (Nasdaq: NVET) opened for trading at $9.12 after pricing 4,000,000 ordinary shares at a price to the public of $10.00 per share, below the expected $13.00-$16.00 range.
BofA Merrill Lynch and Cowen and Company are acting as joint lead book-running... More
